These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30104271)

  • 1. Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation.
    Yasu T; Konuma T; Oiwa-Monna M; Kato S; Tanoue S; Isobe M; Mizusawa M; Kuroda S; Takahashi S; Tojo A
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
    Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
    Diagn Microbiol Infect Dis; 2018 Feb; 90(2):123-131. PubMed ID: 29203252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia.
    Noguchi S; Takahashi N; Ito M; Teshima K; Yamashita T; Michishita Y; Ohyagi H; Shida S; Nagao T; Fujishima M; Ikeda S; Ito I; Fujishima N; Kameoka Y; Saitoh H; Tagawa H; Hirokawa M; Sawada K
    Int J Clin Oncol; 2013 Dec; 18(6):983-7. PubMed ID: 23076821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
    Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
    J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
    Döring M; Hartmann U; Erbacher A; Lang P; Handgretinger R; Müller I
    BMC Infect Dis; 2012 Jul; 12():151. PubMed ID: 22747637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M; Letscher-Bru V; Herbrecht R
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations.
    Cannon JP; Garey KW; Danziger LH
    Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How low can you go? Use of low- and standard-dose liposomal amphotericin B for treatment of invasive fungal infections.
    Kassamali Z; Danziger LH; Glowacki RC; Schwartz DN
    Int J Infect Dis; 2013 Aug; 17(8):e615-20. PubMed ID: 23474174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study.
    Okada N; Azuma M; Imanishi M; Zamami Y; Kirino Y; Nakamura T; Teraoka K; Abe M; Ishizawa K
    Clin Ther; 2018 Feb; 40(2):252-260. PubMed ID: 29305017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Hypokalemia as a Side Effect of Liposomal Amphotericin in Pediatric Patients.
    Kobayashi R; Keino D; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
    Pediatr Infect Dis J; 2018 May; 37(5):447-450. PubMed ID: 28945677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
    Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
    Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children.
    Sunakawa K; Tsukimoto I; Tsunematsu Y; Honda M; Iwai N; Maniwa T; Haigo H; Suzuki K; Mori T
    J Infect Chemother; 2012 Aug; 18(4):456-65. PubMed ID: 22286407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of treatment with liposomal amphotericin B in elderly patients at least 65 years old with hematological diseases.
    Ueda S; Miyamoto S; Kaida K; Chizuka A; Kojima R; Takano J; Ogasawara T; Miyamoto K; Miyakoshi S; Kanda Y
    J Infect Chemother; 2016 May; 22(5):287-91. PubMed ID: 26908230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin for secondary prophylaxis: A systematic review and meta-analysis.
    Javandoust Gharehbagh F; Roshanzamiri S; Farjami M; Hatami F; Lotfollahi L; Kazeminia N; Hatami F; Shokouhi S; Alavi Darazam I
    J Oncol Pharm Pract; 2024 Jul; 30(5):919-929. PubMed ID: 38720564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical efficacy and safety of liposomal amphotericin B in the salvage treatment of invasive fungal disease in patients with hematological diseases].
    Wu YB; Jiang SS; Wu YX; Liu B; Jing YT; Bao HY; Ma X; Wu DP; Hu XH
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jul; 45(7):666-671. PubMed ID: 39231771
    [No Abstract]   [Full Text] [Related]  

  • 20. [Liposomal-amphotericin B efficacy and safety].
    Hamada Y; Komatsu T; Seto Y; Matsubara H; Kume H; Sunakawa K; Yago K
    Kansenshogaku Zasshi; 2010 Mar; 84(2):193-8. PubMed ID: 20420165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.